Skip to main content
Aurinia Pharmaceuticals Inc. logo

Aurinia Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · AUPH ISIN · CA05156V1022 LEI · 5299008YP2BW4570ML28 US Manufacturing
Open in API
Filings indexed 582 across all filing types
Latest filing 2016-03-29 Regulatory Filings
Country CA Canada
Listing US AUPH

About Aurinia Pharmaceuticals Inc.

https://www.auriniapharma.com

Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering therapies for patients with severe autoimmune diseases that have high unmet medical needs. The company's principal product is LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN), a serious complication of systemic lupus erythematosus. Aurinia's research and development efforts are centered on immunomodulating therapies for various autoimmune and kidney-related diseases.

Recent filings

Filing Released Lang Actions
AURINIA PHARMACEUTICALS INC. 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Aurinia Pharmaceuticals Inc., which is a report of a foreign private issuer pursuant to SEC rules. Form 6-K filings are typically used to provide current reports and updates by foreign companies and are not annual or quarterly reports themselves. The document includes a news release about a clinical study result, which is typical content for a 6-K. The document length is short (2157 characters), and it does not contain detailed financial statements or comprehensive financial analysis. Therefore, it is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is also not a report publication announcement or certification. Given the nature of Form 6-K filings, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2016-03-29 English
AURINIA PHARMACEUTICALS INC.
Interim / Quarterly Report Classification · 85% confidence The document is a Form 6-K, which is a report of a foreign private issuer submitted to the SEC under the Securities Exchange Act of 1934. It includes a news release about quarterly and full year financial results and operational highlights. The document length is only 2119 characters, which is quite short and primarily serves as a report submission rather than containing full financial statements or detailed analysis. Form 6-K filings typically correspond to interim or quarterly reports for foreign issuers, but given the short length and the nature of the content (news release summary), it aligns best with an Interim / Quarterly Report (IR) classification, as it reports quarterly and full year financial results. The document is not a full annual report (10-K), nor is it a simple announcement of report publication (RPA). Therefore, the best fit is IR with moderate to high confidence.
2016-03-18 English
ANNUAL REPORT FOR THE FISCAL YEAR ENDED DECEMBER 31, 2015
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT FOR THE FISCAL YEAR ENDED DECEMBER 31, 2015' and is filed on Form 40-F with the SEC, which is a form used by certain foreign private issuers to file their annual reports. The text includes detailed references to audited consolidated financial statements, management's discussion and analysis, internal control assessments, audit committee information, and other comprehensive annual reporting elements. It explicitly states it is an annual report for the fiscal year ended December 31, 2015, and contains substantive financial data and management analysis. Therefore, this document fits the definition of an Annual Report (10-K equivalent for foreign private issuers).
2016-03-18 English
AURINIA PHARMACEUTICALS INC. 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Aurinia Pharmaceuticals Inc., which is a report of a foreign private issuer pursuant to SEC rules under the Securities Exchange Act of 1934. The text includes the form header, company identification, and a news release exhibit about FDA fast track designation. The document length is 2116 characters, which is relatively short and primarily serves as a regulatory filing to inform the SEC and public about a material event. It does not contain detailed financial statements, management discussion, or other comprehensive report content. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings like Form 6-K that do not fit other specific categories.
2016-03-02 English
AURINIA PHARMACEUTICALS INC. 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Aurinia Pharmaceuticals Inc., which is a report of a foreign private issuer pursuant to SEC rules. Form 6-K filings are typically used by foreign companies to provide current reports to the SEC, often including press releases, presentations, or other material information. The document includes a news release about a presentation at a healthcare conference, but does not contain financial statements or detailed financial analysis. The document length is 2107 characters, which is relatively short and consistent with a regulatory filing rather than a full report. There is no indication that this is an annual report, earnings release, or other detailed financial report. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2016-03-01 English
SC 13G/A
Major Shareholding Notification
2016-02-16 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.